Prilenia

[Available On-Demand]
Prilenia is a clinical stage biotech startup founded in 2018 with the purpose of improving the lives of patients and their families by developing treatments for neurodegenerative and neurodevelopmental disorders. Prilenia is backed by a group of well-respected investors: Talisman, Forbion, Morningside, Sectoral and ALS Investment Fund. The Company is based in Naarden, the Netherlands, Herzliya, Israel and Boston, MA in the U.S.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Israel
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
Pridopidine
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Prilenia